Fresenius, NXStage getting renewed questions from FTC, Capitol Forum says

 Questions about (FMS) $2B acquisition of NxStage (NXTM) have led to a renewed focus by the FTC on the deal’s potential impact on the entry into the home hemodialysis machine market, putting the companies’ plans to close the transaction by the end of the year in jeopardy, The Capitol Forum reports, citing sources familiar with the matter.
https://thefly.com/landingPageNews.php?id=2830645